Published in:
01-07-2007 | CASE REPORT
Effect of Imatinib Mesylate in a Patient with a Metastatic Gastrointestinal Stromal Tumor with a c-kit Mutation in Exon 11
Authors:
Keisuke Kubota, Atom Katayama, Yutarou Takeshita, Koji Nozaki, Tetsuya Ueda, Kazuhiro Imamura, Naoki Hiki, Sachiyo Nomura, Michio Kaminishi, Ken-Ichi Mafune
Published in:
Digestive Diseases and Sciences
|
Issue 7/2007
Login to get access
Excerpt
A gastrointestinal stromal tumor (GIST) is a group of mesenchymal neoplasms that have been defined as KIT (CD117) or CD34 immunostaining-positive mesenchymal spindle cells or epithelioid neoplasms originating from the gastrointestinal tract [
1‐
3]. Up to 90% of GISTs harbor a mutation in
c-kit leading to KIT receptor autophosphorylation and ligand-independent activation, and such mutations appear to play a central role in the pathogenesis of GISTs [
3,
4]. The
c-kit mutations in GISTs are found most commonly in exon 11 and exon 9, but only rarely in exons coding for the kinase domain. The clinical significance and response to imatinib by the different types of mutation are not yet certain [
4,
5]. …
